Q-omics provides the consensus-scored PAFAH1B3 profile across patient tissues and cancer cell-line models. PAFAH1B3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PAFAH1B3 is differentially expressed in 16, with the highest sampling consensus in LUAD. Additionally, PAFAH1B3 protein abundance shows 22,174 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, LUAD, and GBM as cancer lineages where PAFAH1B3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PAFAH1B3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PAFAH1B3 survival associations across molecular data types. PAFAH1B3 RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PAFAH1B3 RNA expression–survival associations across cancer types. High PAFAH1B3 expression shows unfavorable associations in ACC, MESO, LIHC, SKCM, SARC and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PAFAH1B3 RNA expression.
This table summarizes PAFAH1B3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PAFAH1B3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PAFAH1B3 shows higher tumor expression in LUAD, BLCA, COAD, STAD, LIHC and LUSC. The LUAD box plot shows higher PAFAH1B3 RNA expression in tumor versus normal tissue (log2 FC = +2.573, t-test p < 0.001).
This table shows molecular features associated with PAFAH1B3 in patient tissues and cancer cell lines. In patient samples, PAFAH1B3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PAFAH1B3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
